Abstract: The present invention provides, in certain aspects, a method of identifying a subject as having an increased risk of developing multiple sclerosis, comprising detecting in the subject the presence of a nucleotide variant in the interleukin 7 receptor alpha chain gene, whereby the presence of said variant identifies the subject as having an increased risk of developing multiple sclerosis.

Abstract: A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 49 to 51 or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium.

Abstract: This invention relates to a method of determining the presence of certain HLA alleles, such as HLA-B*1502 or HLA-B*5801, and a kit for carrying out this method. Also disclosed is a method for assessing whether a patient is at risk for developing adverse drug reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, or hypersensitivity syndrome) based on the presence or absence of a genetic marker (e.g., HLA-B*1502, HLA-B*5801, or HLA-B*4601).

Abstract: Disclosed is a gene mutation associated with peripheral neuropathy associated with sensorineural hearing loss and optic neuropathy. More specifically, disclosed are: a polynucleotide comprising a mutation associated with peripheral neuropathy associated with sensorineural hearing loss and optic neuropathy, or a complementary polynucleotide thereof; a polynucleotide which hybridizes with said polynucleotide; a polypeptide which is encoded by said polynucleotide; an antibody which binds to said polypeptide; and a microarray chip and a kit, which comprise said polynucleotide. Also disclosed are a method for diagnosing a syndrome of peripheral neuropathy associated with sensorineural hearing loss and optic neuropathy, a method for detecting the mutation, and a method for screening drugs for treating these diseases.

Abstract: The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in osteoarthritis and/or in a particular stage of osteoarthritis, as well as a means of selecting the novel biomarker combinations. The measurement of expression of the products of the biomarkers and combinations of biomarkers demonstrates particular advantage in one or more of the following: (a) diagnosing individuals as having arthritis, (b) differentiating between two stages of osteoarthritis (OA) and (c) diagnosing individuals as having a particular stage of OA. Polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers are within the scope of the invention as are kits containing the polynucleotides and proteins and the use of the polynucleotides and proteins.

Abstract: A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 65 to 67 or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium.

Abstract: A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 40 to 42 or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium.

Abstract: A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 43 to 45 or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium.

Abstract: A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 52 to 54 or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium.

Abstract: This invention provides a novel marker of vesicoureteral reflux or interstitial cystitis and a simple and non-invasive method for detecting vesicoureteral reflux or interstitial cystitis. This method comprises detection of uroplakin expression in a sample obtained from a subject.

Abstract: The physiological regulation of intake, growth and energy partitioning in animals is under the control of multiple genes, which may be important candidates for unraveling the genetic variation in economically relevant traits in beef production. The present invention relates to the identification of single nucleotide polymorphisms (SNPs) and their haplotypes, across the bovine genome in genes encoding polypeptides associated with feed efficiency, and their associations with residual feed intake in beef production. The invention further encompasses methods and systems, including network-based processes, to manage the SNP data, haplotype data and other data relating to specific animals and herds of animals, veterinarian care, diagnostic and quality control data and management of livestock which, based on genotyping, have predictable meat quality traits, husbandry conditions, animal welfare, food safety information, audit of existing processes and data from field locations.

Abstract: The invention provides methods and compositions for diagnosing risk of low BMD and risk of osteoporosis based on the detection of SNP identity for human chromosome 1p36 polymorphisms designated in the NCBI SNP database (dbSNP) as rs2794328, rs446529, rs397559 and rs1802353.

Abstract: A first embodiment is a breast cancer prognosticator comprising a detection mechanism consisting a 15-gene signature. In addition there are embodiments comprised of 23-gene signatures and 28-gene signatures. The 28-gene signature may also be used for the prognosis of ovarian cancer. A second embodiment is a method to determine metastatic potential, relapse potential, or both in breast cancer patients comprising collecting a sample from an individual, removing marker-derived polynucleotide from said sample, using a detection mechanism to search for positive matches of said polynucleotides and either the 15, 23, or 28-gene signatures, and developing a quantitative expression profile. Utilizing risk analysis the individual can be placed into one of two or more groups predicting risk and/or clincopathogic variables.

Abstract: The present invention provides methods for the prediction and diagnosis of autoimmune diseases, including Systemic Lupus Erythematosus, using single nucleotide polymorphism in TNFAIP3 (A20).

Abstract: The present invention provides an isolated polynucleotide comprising at least one polymorphic nucleotide sequence, for example, the major alleles of the SNPs described as rs12583006, rs1224141, and rs1248930 and diagnostic assays for detecting the presence of these polymorphism associated with a condition associated with BLyS activity, such as hematological malignancy including B cell malignancies. The diagnostic assays are useful in predicting an individual's likelihood of developing a condition associated with BLyS activity, such as hematological malignancies, and for methods for treating an individual clinically diagnosed with a condition associated with BLyS activity, such as prediction of a patient's likelihood to respond to a specific drug treatment. The invention also provides an array of nucleic acid molecules immobilized on a solid surface, where at least one of the nucleic acid molecules comprises a BLyS polymorphic nucleic acid molecule.

Abstract: This invention relates to a method of determining the presence of certain HLA alleles, such as HLA-B*1502 or HLA-B*5801, and a kit for carrying out this method. Also disclosed is a method for assessing whether a patient is at risk for developing adverse drug reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, or hypersensitivity syndrome) based on the presence or absence of a genetic marker (e.g., HLA-B*1502, HLA-B*5801, or HLA-B*4601).

Abstract: The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment.

Abstract: The disclosure provides methods and compositions useful for identifying a subject's predisposition to lithium treatment.

Abstract: The invention provides methods and compositions for rapid, sensitive, and highly specific nucleic acid-based (e.g., DNA based) detection of a BK virus in a sample. In general, the methods involve detecting a target nucleic acid having a target sequence of a conserved region of BK viral genomes. The invention also features compositions, including primers, probes, and kits, for use in the methods of the invention.

Abstract: The present invention relates to a method of identifying an increase in risk for type II Diabetes mellitus, venous thrombosis, or pulmonary embolism in a subject, wherein the presence of an amino acid exchange at position 286 from valine (Val) to alanine (Ala) in the EDG5 protein in a biological sample taken from the subject.